Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orthofix MedicalOFIX -1.85%57 Future 3-5Y EPS without NRI Growth Rate is 29.05 as of Aug. 21, 2026. GuruFocus rates OFIX with a GF Score™ of 57/100 and a GF Value™ of $13.93 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 279 Medical Devices & Instruments companies, Orthofix Medical ranks better than 69.18% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Orthofix Medical's Future 3-5Y EPS without NRI Growth Rate is 29.05.
Orthofix Medical (NAS:OFIX) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Orthofix Medical Future 3-5Y EPS without NRI Growth Rate Related Terms
OFIX vs VMD, VREX, KIDS: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Orthofix Medical's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orthofix Medical Future 3-5Y EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Orthofix Medical's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 29.05 mean?
Orthofix Medical (OFIX) has a Future 3-5Y EPS without NRI Growth Rate of 29.05 as of Aug. 21, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Orthofix Medical and its competitors. According to the industry distribution chart, Orthofix Medical ranks #86 out of 279 companies in the Medical Devices & Instruments industry, placing it in the top 30.8%.
Is Orthofix Medical's Future 3-5Y EPS without NRI Growth Rate too high?
Orthofix Medical's current Future 3-5Y EPS without NRI Growth Rate is 29.05. The Medical Devices & Instruments industry median Future 3-5Y EPS without NRI Growth Rate is 20.97. Orthofix Medical's value of 29.05 is 38.5% above this industry median. Based on the distribution chart, Orthofix Medical ranks #86 out of 279 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Orthofix Medical has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orthofix Medical's Future 3-5Y EPS without NRI Growth Rate compare to VMD and VREX?
According to the Medical Devices & Instruments industry distribution chart, Orthofix Medical ranks #86 out of 279 companies for Future 3-5Y EPS without NRI Growth Rate. This puts Orthofix Medical in the upper half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 20.97. Orthofix Medical's value of 29.05 is 38.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median Future 3-5Y EPS without NRI Growth Rate among Medical Devices & Instruments companies is 20.97, based on 279 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orthofix Medical's current Future 3-5Y EPS without NRI Growth Rate of 29.05 is 38.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Orthofix Medical and its competitors. For the Medical Devices & Instruments industry, the median Future 3-5Y EPS without NRI Growth Rate is 20.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orthofix Medical's current Future 3-5Y EPS without NRI Growth Rate is 29.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthofix Medical stock overvalued right now?
Based on GuruFocus' analysis, Orthofix Medical (OFIX) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.93, compared to a current price of $9.83 — trading 29.5% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 29.05 and 38.5% above the Medical Devices & Instruments industry median of 20.97. Orthofix Medical's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Orthofix Medical (OFIX), the current Future 3-5Y EPS without NRI Growth Rate is 29.05 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orthofix Medical (OFIX) Overvalued in 2026?
Based on GuruFocus' analysis, Orthofix Medical stock appears to be undervalued.
The current stock price of $9.83 is trading 29.5% below its estimated GF Value™ of $13.93.
GuruFocus considers Orthofix Medical to be Modestly Undervalued.
Key valuation signals for OFIX:
Future 3-5Y EPS without NRI Growth Rate: 29.05
GF Value™: $13.93 vs. price of $9.83 (29.5% below fair value)
Industry Position: 38.5% above the Medical Devices & Instruments median (#86 of 279)
No single metric tells the full story. See the OFIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
57GF Score
Get the complete analysis for OFIX
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OFIX has been successfully added to your 
